Avantor Inc.

Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The firm operates through the following segments: the Americas, Europe, and AMEA. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Avantor Inc. reports Q1 revenue decline, eyes semiconductor market rebound

Avantor Inc. navigated challenges in Q1 with revenue declines due to destocking and semiconductor downturn, while showcasing strengths in innovation and acquisitions performance.
Management's confidence in the long-term strategy and focus on margin improvement present opportunities for growth and recovery in 2023, despite ongoing market challenges.
Strategic approaches to address destocking headwinds and market dynamics in different regions position Avantor Inc. for potential growth and resilience in the coming quarters.
Overall, Avantor Inc. faces challenges from market uncertainties but remains poised to leverage opportunities for growth, innovation, and margin improvement in the evolving landscape.

Avantor Inc. reports Q2 revenue decline, focuses on cost controls

Avantor Inc. faced revenue and EPS cuts in Q2 2023, driven by market challenges in biopharma and semiconductors. The company focused on cost savings, debt reduction, and operational efficiency. Challenges included limited visibility in research space and mid- to high single-digit organic decline in bioproduction.

Avantor Inc. reports Q3 revenue contraction, eyes growth opportunities

Avantor Inc. navigated challenges in Q3 2023 with a focus on growth and operational improvements.
Management's cautious yet optimistic stance reflects a strategic approach to customer sentiment and inventory health.
Outlook for 2024 remains uncertain, but the company is positioned to capitalize on opportunities in key markets.
Analyst questions addressed various topics, highlighting the company's proactive engagement with stakeholders.

Avantor Inc. exceeds Q4 expectations, eyes cost savings and margin growth

Avantor Inc. delivered solid Q4 results, focusing on executing business model transformation and driving growth strategy. Despite challenges in market conditions and revenue decline, the company is optimistic about cost-saving initiatives and margin improvement opportunities.

Avantor Inc. reports Q1 revenue decline but optimistic on growth

Avantor Inc. delivered mixed performance in Q1 2024 with revenue decline but strong margin and debt reduction. Despite challenges in certain segments and regions, the company remains optimistic about growth opportunities in key markets and cost-saving initiatives.

Avantor reports solid Q2 earnings, eyes growth in Bioprocessing segment

Avantor Inc.'s Q2 2024 performance showcased solid revenue, margin improvement, and strong segmental growth. While facing challenges in organic revenue decline and segmental performance, the company's focus on cost transformation and positive outlook signal resilience and potential for growth. Avantor's opportunities lie in leveraging Bioprocessing momentum and cost-saving initiatives for sustained performance enhancement.

Avantor Inc. reports solid Q3 performance and accelerates growth strategies

Avantor's Q3 performance reflects resilience and strategic focus amidst market challenges, with notable achievements in revenue, margin, and divestiture.
The company's strengths in innovation, operational excellence, and market positioning position it well for long-term growth and profitability.
While facing challenges in certain segments and cost transformation, Avantor's opportunities in renewable energy, cash flow, and market growth are promising.

Avantor Inc. reports solid Q4 earnings, targets growth through innovation

Avantor Inc. delivered solid financial performance in Q4 2024, focusing on debt reduction, cost savings, and strategic initiatives to drive growth and profitability.
While facing challenges in managing financial leverage and achieving margin targets, the company is well-positioned to capitalize on opportunities in digital innovation and partnerships.
With a clear roadmap for 2025, including revenue growth targets and cost-saving objectives, Avantor aims to strengthen its market position and deliver value to stakeholders.
Investors can look forward to Avantor's continued progress in leveraging technology, optimizing operations, and driving earnings growth in the upcoming year.

Avantor Inc. reports CEO transition and revenue challenges in Q1 2025

Avantor Inc. navigated a CEO transition and revenue challenges in Q1 2025, taking immediate actions to drive growth and operational excellence in the Lab business. Despite facing funding caution and tariff impacts, the company demonstrated strength through cost transformation initiatives and strategic partnerships to expand its market presence. Analysts' inquiries into revenue breakdown and competitive dynamics underscore the importance of Avantor's focus on growth, efficiency, and cost discipline to sustain long-term success.

Avantor transitions CEO, reports flat Q2 revenue, focuses on margins

Avantor's Q2 performance reflected stable revenue but highlighted challenges in Bioscience Production and margin pressures. The company's strategic wins and cost-saving initiatives position it well for future growth and profitability. While facing near-term headwinds, Avantor remains focused on expanding margins and driving operational efficiency. Revised outlooks underscore the company's adaptability and commitment to long-term value creation for shareholders.

Avantor Inc. reports Q3 revenue decline, unveils Revival plan

Avantor's Q3 performance faced revenue decline in key segments, prompting the Avantor Revival plan to address challenges and capitalize on opportunities for growth and efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. Its portfolio includes biopharma, healthcare, education and government, as well as advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The company operates through the Laboratory Solutions segment and Bioscience Production. The Laboratory Solutions segment focuses on research, diagnostic, and quality control workflows. The Bioscience Production segment focuses on high-purity materials for bioprocessing and medical technologies. Avantor was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.